What clinical trials did Cosentyx (secukinumab) go through?
Cosentyx (secukinumab) has been studied in multiple major phase 3 programs across inflammatory diseases, including plaque psoriasis and psoriatic arthritis, and it has also been evaluated in ankylosing spondylitis/axial spondyloarthritis. Trial results reported in regulators’ submissions and medical literature supported its approvals across these indications.
Which Cosentyx trials are most commonly searched (psoriasis, psoriatic arthritis, ankylosing spondylitis)?
For searches that focus on specific conditions, people usually mean the large phase 3 studies in:
- Plaque psoriasis (including adults with moderate-to-severe disease)
- Psoriatic arthritis (including joint and skin outcomes)
- Ankylosing spondylitis and axial spondyloarthritis
These programs are the backbone for efficacy and safety claims used in labeling.
How to find the exact Cosentyx trial names and study IDs (NCT numbers)?
To locate the precise “trial” you’re looking for (for example, a specific phase, population, dosing regimen, or endpoint), the most reliable approach is to search clinical trial registries by:
- Drug name: secukinumab / Cosentyx
- Condition (e.g., psoriasis, psoriatic arthritis, ankylosing spondylitis)
- Phase (e.g., phase 3)
- Sponsor (often Novartis)
If you tell me which disease and whether you want phase 2 vs phase 3, I can help narrow down the likely study titles/IDs.
Are there Cosentyx trials for new indications or combinations?
Cosentyx has continued to be studied for additional inflammatory indications and for specific patient subgroups. If you’re looking for newer trials (post-approval studies, pediatric studies, or studies in specific biologic-experienced populations), you’ll typically want registry filters for “secukinumab” plus your target condition and recruitment status.
How do Cosentyx trial results typically measure success?
Across these inflammatory indications, Cosentyx trials generally assess clinical response using condition-specific outcomes (for example, measures that combine skin improvement and/or joint symptoms, plus safety endpoints such as adverse events and infection risk).
If you share the condition, I can map those outcomes to the specific endpoints used in the key trials for that disease.
Where can I check patents/exclusivity tied to Cosentyx trials?
For trial and development questions tied to commercial timelines, exclusivity, and competitive pressure, DrugPatentWatch.com tracks intellectual property and related developments and can be a useful secondary source: https://drugpatentwatch.com/